Founded in 1989, OrbiMed is a New York-based healthcare-dedicated investment firm managing approximately $5 billion in assets. It invests across the spectrum of healthcare companies, from private start-ups to large multinational corporations, focusing on biopharmaceuticals, life sciences, digital health, medical devices, and diagnostics sectors globally.

Founded in Boston in 2004, RA Capital is an investment firm specializing in life sciences and drug development. Its team, with backgrounds in biology, chemistry, medicine, and industry experience, invests in early-stage companies with promising technologies and products across healthcare and life science sectors.

Novo Holdings, established in 1999, is a Danish asset management firm based in Copenhagen. It serves as the investment arm of the Novo Nordisk Foundation, managing its assets and wealth. The company's primary focus is the life science sector, with a diversified portfolio comprising equities, bonds, real estate, infrastructure, and private investments. Novo Holdings maintains a significant influence on Novo Nordisk A/S and Novozymes A/S, ensuring these companies align with the Novo Group's visions and values. It also invests in early and growth-stage life science companies through its venture capital arm, Novo Ventures, which targets investments ranging from USD 5 million to USD 30 million.

The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.

Perceptive Advisors, established in 1999, is a New York-based investment management firm specializing in the life sciences sector. It invests in both private and public biotechnology, pharmaceutical, medical device, diagnostics, and health services companies across their lifecycle, from seed and early-stage ventures to public equities. The firm employs a long/short equity strategy and conducts in-house research to identify promising opportunities. Perceptive Advisors also offers customized debt financing solutions through its Perceptive Credit Opportunities Fund.

Founded in 2006, Qiming Venture Partners is a leading China-based venture capital firm with offices across China and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries.

Founded in 2005, Y Combinator is a California-based startup accelerator and early-stage venture capital firm. It provides funding, mentorship, and resources to early-stage companies across various industries, with a focus on technology, healthcare, and finance. The organization helps founders refine their business models and products through an intensive three-month program in Silicon Valley, culminating in Demo Day presentations to investors.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that focuses on biotechnology and life sciences companies in the United States. The firm seeks to invest in pharmaceutical and biotechnology ventures, including oncology and other healthcare technologies, with a goal of supporting entrepreneurs in turning ideas into developed therapies. It emphasizes collaboration with ambitious partners and aims to advance biotech innovation and important new therapies by providing capital and advisory support. The organization also operates as a registered investment adviser, offering investment advisory services to guide portfolio companies through growth and development.

New Enterprise Associates is a venture capital firm founded in 1977 and based in Menlo Park, California, with offices in the United States, India and China. It makes investments across technology and healthcare startups at multiple stages, from seed to growth, including software, cloud, data, internet services, fintech, AI, e-commerce, and enterprise technology, as well as healthcare information technology, life sciences, medical devices, and biopharma. It also considers energy technology and infrastructure opportunities, such as solar, batteries and smart grids. The firm pursues a global approach, with activity in the United States, Asia and other regions, and supports companies through rounds of financing ranging from small to sizable investments as they scale. NEA focuses on building portfolios in software, IT services, consumer technology, and healthcare technology, backing ambitious entrepreneurs across sectors and geographies.

Novartis is a global healthcare company based in Switzerland, providing innovative medicines and solutions to address evolving patient needs worldwide. With over 100,000 employees across 140 countries, they focus on discovering new treatments in areas such as oncology, immunology, neuroscience, and cardiovascular diseases.

Established in 2000 by Bill and Melinda Gates, this foundation is dedicated to enhancing healthcare, reducing extreme poverty globally, and expanding educational opportunities. It operates regionally with offices in Seattle, Washington D.C., New Delhi, Beijing, and London.

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines across neuroscience, cardiometabolic, cancer, and immunology. It operates manufacturing and distribution facilities in the United States, Puerto Rico, and 25 other countries, with products sold in about 135 countries. Its portfolio includes Verzenio for cancer; Mounjaro and Zepbound for cardiometabolic indications; Jardiance and Trulicity; Humalog and Humulin for diabetes; and Taltz and Olumiant for immunology.

Biotechnology Value Fund is a private investment partnership based in San Francisco, focusing on fundamentally-driven public biotechnology investments. Established in 1993, the fund aims to create concentrated, long-term investments in small-cap biotechnology firms. It emphasizes rigorous due diligence and continuous monitoring of its portfolio to ensure sustainable growth. Furthermore, Biotechnology Value Fund is dedicated to collaborating with its portfolio companies, fostering partnerships that support mutual success in the biotechnology sector.

Versant Ventures is a healthcare-focused venture capital firm based in San Francisco with offices in Canada, the United States and Europe. Founded in 1999, it invests across the healthcare sector at all stages, with emphasis on the discovery and development of novel therapeutics, medical devices, biotechnology and pharmaceuticals. The firm combines investment, operating and scientific expertise to take a hands-on approach to building portfolio companies, helping entrepreneurs translate science into commercial therapies and technologies. It has supported numerous portfolio companies through acquisitions or IPOs, reflecting a track record of guiding early stage ventures toward meaningful exits in biopharma, life sciences and related fields.

Vivo Capital, established in 1996, is a global investment firm headquartered in Palo Alto, California, with a presence in Asia. It manages approximately $5.8 billion in assets, invested across over 290 public and private healthcare companies worldwide. The firm's 50-strong team comprises professionals with diverse backgrounds, including physicians, scientists, entrepreneurs, and industry experts. Vivo Capital operates a multi-fund platform, covering growth equity, private equity, venture capital, and public equity, with a broad focus on healthcare sectors such as biotechnology, pharmaceuticals, medical devices, and healthcare services. It primarily invests in the largest healthcare markets.

Founded in 1986, Morningside Group is a venture capital firm based in the greater Boston area. It invests in companies with innovative science and technology across life sciences, digital health, AI, materials, and technology sectors.

Venrock, established in 1969, is a venture capital firm headquartered in Palo Alto, California, with additional offices in New York. It specializes in seed and early-stage investments, primarily in technology and healthcare sectors. The firm partners with entrepreneurs to build successful, enduring companies, with a notable track record including Apple, Athenahealth, and Gilead Sciences. Venrock also manages dedicated funds for healthcare investments, such as Venrock Healthcare Capital Partners, focusing on both private and public biotechnology companies.

The National Science Foundation (NSF) is an independent federal agency established in 1950 and based in Alexandria, Virginia. It is dedicated to supporting research and education in science and engineering across a wide range of disciplines. The NSF provides significant non-dilutive funding, up to $1.5 million, to startups and small businesses through its America's Seed Fund initiative, which is part of the Small Business Innovation Research (SBIR) program mandated by Congress. With an operating budget of approximately $7.8 billion, the NSF is committed to advancing fundamental research and education, thus fostering innovation and technological development in the United States.

Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.

SOSV, established in 1995 and headquartered in Princeton, New Jersey, is a global venture capital firm specializing in early-stage investments. It focuses on deep tech innovations in the health and environmental sectors, supporting founders with breakthrough technologies through its HAX and IndieBio startup development programs. SOSV provides resources, facilities, and lab equipment to accelerate product development and scale, with a track record of helping its portfolio companies secure subsequent funding rounds led by top-tier investors.

Founded in 1934, Janus Henderson Investors is a global asset management firm headquartered in London. It specializes in delivering investment performance and services to institutional, retail, and high-net-worth clients across various asset classes such as equities, fixed income, property, and alternatives.

Founded in 2007, Innovate UK is a non-profit organization based in Swindon, UK. It supports businesses across various economic sectors by offering funding services to promote science and technology innovations.

Sanofi is a global pharmaceutical company headquartered in Paris that researches, develops, manufactures, and markets medicines and vaccines for a broad range of diseases. Its portfolio covers diabetes, oncology, immunology, cardiovascular diseases, and rare disorders, along with consumer healthcare products. Sanofi pursues innovation across biologics and small-molecule therapies and maintains a robust vaccine program to address infectious diseases. The company emphasizes patient-oriented research and collaborates with partners to bring new treatments to patients worldwide.

Pfizer, established in 1849, is a leading global pharmaceutical company headquartered in the United States. Its core business involves the discovery, development, manufacture, and sale of prescription medicines, vaccines, and health care products. Pfizer's extensive portfolio spans various therapeutic areas, focusing on wellness and prevention, as well as treatments and cures for numerous diseases. Notable products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. With approximately 50% of its sales coming from international markets, including significant contributions from emerging markets, Pfizer's global presence is substantial. The company is committed to providing access to safe, effective, and affordable medicines, driven by its purpose to improve patient outcomes and enhance overall health. Pfizer Venture Investments, its corporate venture capital arm, invests in emerging companies developing transformative medicines and technologies to further strengthen its pipeline. Additionally, the Pfizer Foundation, an independent non-profit, supports global health strategies and community involvement through funding and resources.

RTW Investments, LP is an employee-owned hedge fund manager based in New York, with additional offices in London and Shanghai. Established in 2009, the firm specializes in investments within the healthcare sector, focusing on life sciences, big data, and digital health. RTW Investments engages in a comprehensive investment strategy that spans the entire lifecycle of healthcare companies, including company creation, early-stage venture capital, alternative financing, and public company investments. The firm conducts thorough in-house fundamental research to inform its investment decisions, managing both pooled investment vehicles and separate client-focused equity and fixed income portfolios.

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Surveyor Capital is a fundamental equities business that operates sector-aligned investment teams focusing on market neutral strategies. The company aims to generate alpha by gaining a deep understanding of each company's strategy, management teams, performance drivers, and industry trends over the medium and long term. With a focus on fundamental analysis, Surveyor Capital strives to achieve success through a comprehensive approach to investment in the equities market.

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. It specializes in seed, early-stage, and growth capital investments primarily within the healthcare sector, with a particular emphasis on biopharma, diagnostics, life sciences, agrifood technology, and technology sectors. The firm is recognized for its strategic approach, providing long-term investment capital to innovative companies that are developing transformative technologies and therapies aimed at improving human health. As a subsidiary of Alexandria Real Estate Equities, Alexandria Venture Investments leverages its deep industry expertise, extensive relationships with investors, and a world-class scientific advisory network to support and fund promising startups and growth-oriented companies in disruptive life science and technology.

Founded in 1986, ARCH Venture Partners is a venture capital firm specializing in investments that bring innovations in life sciences to market. It focuses on companies co-founded by scientists and entrepreneurs, with a strong track record in commercializing technologies from academic research institutions and national laboratories.

Google is a multinational technology company renowned for its search engine, offering services such as Gmail, Google Drive, Google Docs, and YouTube. It specializes in advertising solutions through Google Ads and mobile operating systems with Android, while actively innovating in artificial intelligence and machine learning.

Cormorant Asset Management, established in 2013 and headquartered in Boston, Massachusetts, is an employee-owned hedge fund sponsor. It offers services to pooled investment vehicles, specializing in investments across both public and private markets within the biotechnology and life sciences sectors.

Redmile Group, established in 2007, is a private equity firm headquartered in San Francisco with an additional office in New York. The company specializes in healthcare investments, focusing on venture capital opportunities within the sector.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with additional offices in La Jolla, California; Montreal, Quebec; and Tokyo, Japan. It backs early to later-stage startups in life sciences and information technology across the United States and Europe, focusing on West Coast U.S. and developed European markets. In life sciences, the firm pursues clinical-stage pharmaceutical, biotechnology and medical technology companies, including drug discovery platforms and entities addressing diseases with unmet medical needs, covering therapeutic areas such as oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it funds product-oriented software, enterprise software, service-provider software, and telecommunications infrastructure. Seed investments in both domains typically range from 0.1 million to 1 million, with initial rounds for technology commonly 3-5 million and life science rounds 5-15 million; total commitments generally span 5-15 million for tech and 15-30 million for life sciences. The firm seeks board seats when leading or co-leading early-stage investments.

Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in promising life science companies that exhibit strong management teams and innovative technologies or business models. While its primary investment strategy targets opportunities in China, Lilly Asia Ventures is also open to exploring prospects in other regions of East and South Asia. The firm invests across various stages, including seed, early, and later stages, with particular interest in sectors such as healthcare, life sciences, oncology, manufacturing, and technology-based industries. Through its investments, Lilly Asia Ventures aims to foster the development of innovative solutions that contribute to improved health and quality of life.

Founded in Paris in 1972, Sofinnova Partners is a venture capital firm dedicated to life sciences investments. With over €2 billion under management, the firm actively partners with entrepreneurs from seed to later-stage, focusing on biopharmaceuticals, medical devices, and industrial biotechnology. Sofinnova proactively sources deals, often leading Round A financings, and plays an active role in portfolio companies until exit.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

Logos Capital is a biotechnology-focused investment firm based in San Francisco, California, founded in 2019. The firm specializes in identifying transformative therapies within the healthcare sector by leveraging in-house data analytics alongside scientific and clinical expertise. Logos Capital integrates knowledge from medical, scientific, and statistical fields to enhance its investment diligence, aiming to uncover compelling opportunities in the biotechnology space. The firm employs a fundamental and sector-oriented approach to equity investment, utilizing statistical modeling of clinical trials to bolster confidence in its investment positions. Through this rigorous methodology, Logos Capital seeks to deliver uncorrelated market returns while advancing innovative healthcare solutions.

Rock Springs Capital is an investment company based in Baltimore, Maryland, established in 2013. It specializes in the healthcare and biotechnology sectors, offering advisory services that focus on managing security portfolios and providing portfolio management solutions for businesses and institutional clients. The firm aims to assist clients in optimizing their investment strategies and achieving their financial objectives through its comprehensive management services.

Wellington Management Company, founded in 1928 and headquartered in Boston, Massachusetts, is an investment management firm that caters to a diverse range of institutional clients, including high-net-worth individuals, pension plans, endowments, insurers, and government entities. The firm employs a comprehensive approach to investment management that encompasses equity, fixed income, currency, commodity, and alternative markets. Wellington Management offers various services, including asset allocation, multi-manager strategies, and specialized investment approaches. The firm is known for its focus on both growth and value stocks across small-cap, mid-cap, and large-cap companies, and it manages a variety of investment vehicles, such as mutual funds and hedge funds, to meet the unique needs of its clientele.

Deep Track Capital is a venture capital firm focused on life sciences and biotechnology. Based in Greenwich, Connecticut, it partners with management teams of innovative public and pre-IPO companies, offering capital and strategic support through its network and expertise. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other investors, applying time and resources to help portfolio companies grow.

Deerfield Management is a New York-based investment firm established in 1994 that focuses on healthcare. It operates across investment, information, and philanthropy to support the healthcare ecosystem. The firm provides private and public investments and offers long-term, structured capital to both public and private healthcare companies. Its portfolio spans life sciences, medical devices, diagnostics, digital health, and health services. As an investment adviser, it seeks opportunities in healthcare products and services and aims to accelerate innovation by combining capital with industry insight.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with emphasis on drug discovery and development. It backs early-stage and seed companies in the United States, aiming to build science-driven businesses capable of delivering multiple product opportunities rather than short-term exits. The firm concentrates on oncology and other disease areas including inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system conditions, seeking to support platform-based discoveries with potential for significant therapeutic impact.

Bain Capital, established in 1984, is a global multi-asset alternative investment firm with over $100 billion in assets under management. Headquartered in Boston, Massachusetts, the firm operates through several business units: Private Equity, Public Equity, Credit, and Venture Capital. Bain Capital Private Equity invests in various sectors, including consumer, healthcare, industrials, and technology, across North America, Europe, and Asia. Bain Capital Ventures, the venture capital arm, focuses on seed to growth-stage investments in enterprise software, infrastructure software, and industries being transformed by data. Bain Capital Life Sciences, a dedicated life sciences investment platform, invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Bain Capital Double Impact, the firm's impact investing arm, builds great companies that deliver both competitive financial returns and meaningful, measurable social and environmental good.

Polaris Partners is a venture capital firm based in Boston with offices in Boston and San Francisco that invests across healthcare, life sciences, biotechnology, and technology sectors. The firm backs companies from early-stage to growth across the United States and Europe, with portfolios spanning digital health, patient-provider solutions, data science, genomics, therapeutics, software, and IT. Founded in 1996, Polaris Partners partners with repeat entrepreneurs to support ventures through multiple stages, helping them scale scientific and software-enabled businesses.

Venture Kick is a private philanthropic initiative based in Zurich, Switzerland, founded in 2007 to support Swiss startups at the pre-seed stage. It provides up to 150,000 Swiss francs in funding and offers structured entrepreneurial training aimed at developing sustainable businesses. Entrepreneurs participate in a competitive process, pitching their ideas up to three times for increasing funding amounts, while receiving valuable feedback from expert juries. To date, Venture Kick has supported 600 startup projects with a total of 24.9 million francs, leading to the incorporation of 454 active companies that have created over 6,000 jobs and attracted approximately 2.49 billion francs in subsequent investments. Companies founded by Venture Kick alumni have notably achieved significant recognition, with 55 percent of the TOP 100 Swiss Startup Award in 2018 represented by these ventures. In 2019, the initiative aimed to allocate 4.35 million francs to support idea-stage projects, facilitating the transition of Swiss scientific innovations to global markets.

Foresite Capital is a San Francisco based, multi-stage healthcare and life sciences investment firm that also maintains a New York office. It employs a data-driven, scientifically informed approach to identify and fund startups and growth companies across therapeutics, biotechnology, life sciences infrastructure, and healthcare technology and services. The firm seeks ventures that combine biology and data science to address unmet medical needs and improve patient outcomes. It supports portfolio companies through a multidisciplinary team of scientists, engineers, analysts, and clinicians who help evaluate business models and guide value creation. By investing across early to later stages, Foresite Capital aims to accelerate the development and deployment of breakthrough health solutions through rigorous analysis and strategic partnerships while focusing on long-term impact in healthcare.

EcoR1 Capital is a San Francisco-based investment firm focused on biotechnology. It provides advisory and investment services to biotechnology companies, pursuing venture-style opportunities in both private and public markets and supporting therapies with potential patient impact. Founded in 2012, the firm emphasizes scientific innovation and translational research and draws inspiration from the EcoR1 restriction enzyme. As an investment adviser, EcoR1 Capital collaborates with clients and partners in the biotech sector to identify promising treatments and help companies address unmet medical needs.

HBM Healthcare Investments, established in 2001 and headquartered in Zug, Switzerland, is a venture capital firm specializing in the healthcare sector. It invests globally in mature, emerging companies in human medicine, biotechnology, medical technology, and diagnostics. The firm's portfolio comprises approximately 40 companies, with two-thirds being private, offering high value creation potential. HBM focuses on companies with advanced or market-available products, aiming to generate returns for its broad shareholder base.

Founded in 1980, Atlas Venture is an early-stage venture capital firm based in Cambridge, Massachusetts. It focuses on creating and investing in biotech startup companies led by promising entrepreneurs, with a seed-led venture creation strategy that rigorously selects compelling opportunities to build scalable businesses in life sciences innovation.